Protein degradation as a target for anticancer therapy: molecular mechanisms of efficacy and acquired resistance to proteasome and aminopeptidase inhibitors

被引：0
|
作者：
Peters, G. J. [1 ]
Ossenkoppele, G. J. [2 ]
Cloos, J. [2 ]
Jansen, G. [3 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands
来源：
AMINO ACIDS | 2016年 / 48卷 / 02期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：616 / 616
页数：1
相关论文
共 38 条
  • [21] Acquired Resistance to Bortezomib in Human RPMI-8226 Multiple Myeloma Cells: Molecular Characterization, Cross-Resistance with Other Proteasome Inhibitors but Marked Sensitization to Glucocorticoids
    Franke, Niels E.
    Kaspers, Gertjan L.
    van den Berg, Nynke
    van Zantwijk, Ina
    Vojtekova, Katarina
    Yaqub, Uzma
    Smeets, Serge
    Ylstra, Bauke
    Zweegman, Sonja
    Jansen, Gerrit
    Cloos, Jacqueline
    BLOOD, 2008, 112 (11) : 913 - 913
  • [22] Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray
    Lin, Jing
    Zuo, Jianling
    Cui, Yong
    Song, Chaoli
    Wu, Xiaojun
    Feng, Huaizhi
    Li, Jian
    Li, Shuo
    Xu, Qinian
    Wei, Wenxin
    Qiu, Guanzhong
    He, Hua
    ONCOLOGY REPORTS, 2018, 39 (05) : 2333 - 2341
  • [23] Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review
    Memariani, Zahra
    Abbas, Syed Qamar
    Ul Hassan, Syed Shams
    Ahmadi, Amirhossein
    Chabra, Aroona
    PHARMACOLOGICAL RESEARCH, 2021, 171
  • [24] Differences in efficacy, resistance mechanism and target protein interaction between two PPO inhibitors in Palmer amaranth (Amaranthus palmeri)
    Wu, Chenxi
    Goldsmith, Michael-Rock
    Pawlak, John
    Feng, Paul
    Smith, Stacie
    Navarro, Santiago
    Perez-Jones, Alejandro
    WEED SCIENCE, 2020, 68 (02) : 105 - 115
  • [25] The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors
    Friedman, Ran
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (01):
  • [26] Low Molecular Weight Heparin Ablates Lung Cancer Cisplatin-Resistance by Inducing Proteasome-Mediated ABCG2 Protein Degradation
    Niu, Qi
    Wang, Wei
    Li, Yong
    Ruden, Douglas M.
    Wang, Fenghua
    Li, Yue
    Wang, Fangying
    Song, Jingying
    Zheng, Kun
    PLOS ONE, 2012, 7 (07):
  • [27] miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
    Javanmardi, Sanaz
    Aghamaali, Mahmoud Reza
    Abolmaali, Samira Sadat
    Mohammadi, Samaneh
    Tamaddon, Ali Mohammad
    CURRENT GENE THERAPY, 2016, 16 (06) : 375 - 389
  • [28] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiation Therapy for Brain Metastases From EGFR-mutant Lung Adenocarcinoma
    Hirata, H.
    Nakamura, K.
    Kunitake, N.
    Shioyama, Y.
    Sasaki, T.
    Nonoshita, T.
    Inoue, K.
    Nagashima, A.
    Ono, M.
    Honda, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S102 - S102
  • [29] Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis
    Verbrugge, Sue Ellen
    Assaraf, Yehuda G.
    Dijkmans, Ben A. C.
    Scheffer, George L.
    Al, Marjon
    den Uyl, Debby
    Oerlemans, Ruud
    Chan, Elena T.
    Kirk, Christopher J.
    Peters, Godefridus J.
    Van der Heijden, Joost W.
    de Gruijl, Tanja D.
    Scheper, Rik J.
    Jansen, Gerrit
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (01): : 174 - 182
  • [30] Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms
    Lens-Pardo, A.
    Carretero-Puche, C.
    Anton Pascual, B.
    Capdevila Castillon, J.
    Benavent Vinuales, M.
    Jimenez Fonseca, P.
    Grande, E.
    Perna, C.
    Caminoa, A.
    Rubio-Cuesta, B.
    Sarmentero, J.
    Gil-Calderon, B.
    Llamas, P.
    Soldevilla, B.
    Garcia-Carbonero, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S751 - S751
1234